Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVOLVE Ebola booster follow-on study
ISRCTN10481319Phase 2Completed
- Sponsor
- University of Oxford
- Start
- Sep 2019
- Modality
- Vaccines & Immunotherapeutics, Viral Vectors → Gene Addition/Replacement → Gene Therapies
01
Overview
Phase 2, open-label trial of zabdeno in Ebola virus disease (EVD) (2 arms), sponsored by University of Oxford. Primary endpoint: Humoral and cellular immunity at baseline and 1 year. Started Sep 2019; status: completed.
02
Drugs
zabdeno
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on ISRCTN10481319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN10481319.